G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2026

The g-csf (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $9.48 billion in 2025 to $9.94 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to limited availability of g-csf therapies, growing prevalence of chemotherapy-induced neutropenia, rising oncology patient population, regulatory approvals for first-generation g-csf products, adoption of injectable formulations.

The g-csf (granulocyte colony stimulating factors) market size is expected to see strong growth in the next few years. It will grow to $12.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to launch of novel g-csf products, expansion of biosimilars in emerging markets, increasing use of combination therapies, rising demand for pre-filled syringe formulations, growing investment in supportive care and neutropenia management programs. Major trends in the forecast period include rising demand for biosimilars of g-csf products, increasing adoption of pre-filled syringes and injectable formulations, growth in combination therapies with other growth factors, expansion of g-csf use in oncology and blood disorder treatments, rising awareness of neutropenia management and supportive care.

The mounting prevalence of cancer is set to boost the G-CSF (granulocyte colony stimulating factor) market ahead. Cancer features runaway abnormal cell growth and spread that impairs bodily functions and can prove fatal. This upsurge arises from aging demographics, lifestyle shifts, and environmental hazards heightening malignancy risks. The G-CSF market aids this landscape by supplying growth factors that spur white blood cell formation, curbing infection and sepsis dangers for chemo patients. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, recorded 354,820 new cancer diagnoses in 2023 - 972 daily on average, up 8,605 from 2022. Therefore, the increasing prevalence of cancer is driving the growth of the G-CSF (granulocyte colony stimulating factor) market.

Leading companies in the G-CSF (granulocyte colony stimulating factor) market are advancing hematopoietic innovations like dimeric fusion protein designs to amplify neutrophil output and lower immune reactions in extended-release G-CSF options. Dimeric fusion protein design fuses two G-CSF units into one molecule to prolong duration and sharpen receptor engagement sans PEGylation. For instance, in November 2023, Evive Biotech Inc., a Singapore-based biopharmaceutical company, gained U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), a long-acting biosimilar G-CSF to shorten neutropenia and febrile neutropenia spans in adults on cytotoxic chemo. Ryzneuta, an altered recombinant G-CSF, drives bone marrow neutrophil generation, hastening count rebound. Highlights encompass sustained dosing, fit with diverse chemo protocols, and prefilled syringe convenience. It serves chemo neutropenia prevention, stem cell harvesting, and aid for weakened immunity, yielding perks like reduced shots, stronger compliance, and superior patient results.

In August 2025, Intas Pharmaceuticals Ltd., an India-based biotechnology company, acquired UDENYCA from Coherus BioSciences, Inc. for an undisclosed amount. Through this acquisition, Intas Pharmaceuticals and Accord BioPharma aim to cement global pegfilgrastim dominance, expand FDA-cleared biosimilars, and widen patient access to reliable, adaptable infection-prevention therapies during cancer care. Coherus BioSciences Inc. is a US-based, commercial-stage biopharmaceutical company focused on both biosimilars and innovative immuno-oncology therapies, with a team of industry veterans leveraging deep expertise in biologics development and commercialization.

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the g-csf (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the G-CSF market by increasing the cost of imported biologics, pre-filled syringes, and active pharmaceutical ingredients, leading to higher treatment costs and potential delays in product availability. Segments like pegfilgrastim and filgrastim formulations are most impacted, particularly in North America and Europe where imports are significant. However, tariffs have also incentivized local manufacturing, innovation in biosimilars, and the development of cost-effective G-CSF solutions.

The g-csf (granulocyte colony stimulating factors) market research report is one of a series of new reports that provides g-csf (granulocyte colony stimulating factors) market statistics, including g-csf (granulocyte colony stimulating factors) industry global market size, regional shares, competitors with a g-csf (granulocyte colony stimulating factors) market share, detailed g-csf (granulocyte colony stimulating factors) market segments, market trends and opportunities, and any further data you may need to thrive in the g-csf (granulocyte colony stimulating factors) industry. This g-csf (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

G-CSF (granulocyte colony-stimulating factors) are a type of colony-stimulating factor that support the bone marrow in producing additional white blood cells. They are used to treat patients with certain tumors, chemotherapy-induced neutropenia, or severe persistent neutropenia unrelated to cancer treatment. Filgrastim and Granulocyte Colony-Stimulating Factor are alternative names for G-CSF.

The main types in the G-CSF market are lenograstim, filgrastim, pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that closely resembles or matches naturally occurring human G-CSF. These products come in forms such as tablets, capsules, and others, and are applied in oncology, blood disorders, growth hormone deficiencies, chronic and autoimmune diseases, and related conditions.

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.